Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Tocris Bioscience™ Ruxolitinib

Click to view available options
Quantity:
50 mg
Description
Ruxolitinib is a potent and selective JAK1/2 inhibitor (IC50 values are 3.3 and 2.8 nM, respectively). Exhibits selectivity for JAK1/2 over Tyk2 and JAK3 (∼6-fold and >130-fold, respectively). Exhibits no significant inhibition against a commercial panel of 26 additional kinases. Inhibits JAK2V617F-mediated signaling and proliferation in Ba/F3 cells and HEL cells. Increases survival rates in a JAK2V617F-driven mouse model. Identified as targeting human host proteins that interact with SARS-CoV-2. Orally bioavailable.
Phosphate salt (Cat. No. 7048) also available.
Specifications
Specifications
Chemical Name or Material | (3 R)-3-Cyclopentyl-3-[4-(7 H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol-1-yl]propanenitrile |
CAS | 941678-49-5 |
Quantity | 50 mg |
Target | JAK Kinase Inhibitors |
Molecular Formula | C17H18N6 |
Formula Weight | 2323 |
Purity | 98% |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction